A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension

British Journal of Ophthalmology

Volumn 81, Issue 10, 1997, Pages 867-870

  Friström, Björn ^a   Nilsson, Sven Erik G ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; LATANOPROST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS; MALE; OPEN ANGLE GLAUCOMA; PIGMENTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION;

EID: 0030731123     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.81.10.867     Document Type: Article

References (15)

1. Alm A, Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol 1991;109;1564-8.
2. 2α analogue. Effect on intraocular pressure in patients with ocular hypertension. Br J Ophthalmol 1992;76:214-7.
3. Camras CB, Schumer RA, Marsk A, Lustgarten JS, Serie JB, Stjernschantz J, et al. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch Ophthalmol 1992;110: 1733-8.
4. Friström B, Nilsson SEG. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol 1993;111:662-5.
5. Alm A, Villumsen J, Törnquist P, Mandahl A, Airaksinen J, Tuulanen A, et al. Intraocular pressure-reducing effects of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology 1993;100:1312-7.
6. 2α analogue (PhXA41). An in-hospital, placebo-controlled study. Arch Ophthalmol 1993;111:1351-8.
7. Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology 1993;100:1305-11.
8. Alm A, Widengård I, Kjellgren D, Soderstrom M, Fristrom B, Heijl A, et al. Latanoprost administered once daily causes a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995;79:12-6.
9. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989;49:389-402.
10. 2α-1-isopropylester in the cynomolgus monkey. Exp Eye Res 1989;48:707-16.
11. 2α analog, on aqueous humor dynamics inhuman eyes. Ophthalmology 1993;100:1297-304.
12. 2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111: 1351-8.
13. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 1996; 103:138-47.
14. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-37.
15. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 1995; 102:1743-52.